When I last wrote about the Anglo-Swedish pharmaceuticals company AstraZeneca (NASDAQ: AZN ) in June, further upside to the stock was already unlikely. This prompted a Hold rating on it, breaking the trend from the previous seven Buy ratings on it since 2022. This Manika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gree ...

Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $1.01 per share in its upcoming report, which indicates a year-over-year increase of 16.1%. Revenues are expected to be $13.04 billion, up 13.5% from the year-ago quarter. The consensus EPS estimate for the quarter has undergone a downward revision of 0.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Before ...

Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in three of the past four quarters.Register now to see our 7 Best Stocks for the Next 30 Days report - free today!AstraZeneca (AZN) will report its third-quarter earnings on Nov. 12, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.04 billion and $1.01 per share, respectiv ...

Company News - AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance fraud case [1] - AstraZeneca China President Leon Wang is cooperating with Chinese authorities [1] - In September, five current and former AstraZeneca employees were detained by police in China in connection with multiple investigations [1] - Dozens of the company's senior executives in China potentially have been implicated in an insurance fraud case [2] - The company stated that if requested, it will fully cooperate with the Chinese authorities [2] - Five current and former AstraZeneca employees were detained by police in China in September in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug [3] - AstraZeneca employs roughly 16,000 workers in China and has operated there since 1993 [3] Stock Performance - U S -listed shares of AstraZeneca fell more than 7% Tuesday to close at $66 27 [3] - The shares are down 1 6% in 2024 [3]

Just two weeks ago, Upstream Bio, Inc. UPB closed its upsized initial public offering (IPO) of 17.25 million shares at $17 per share, with gross proceeds of approximately $293 million.Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases with an initial focus on severe respiratory disorders.Piper Sandler initiated coverage on Upstream Bio with an Overweight rating and a price target of $75.William Blair has also initiated coverage of Upstream Bio with an Outp ...

The price could be right for these stocks.A low share price doesn't necessarily mean a stock is valued attractively. For example, you wouldn't invest in a company that markets oceanfront property in Arizona regardless of how low its share price was. However, prices per share can matter to investors who don't have a lot of cash to put to work.If you're in that group, you're in luck. Three Fool.com contributors have identified what they view as magnificent stocks trading at under $100 to buy in November. Here ...

Astrazeneca (AZN) closed at $71.42 in the latest trading session, marking a +0.38% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.41%. On the other hand, the Dow registered a gain of 0.69%, and the technology-centric Nasdaq increased by 0.8%. Heading into today, shares of the pharmaceutical had lost 8.7% over the past month, lagging the Medical sector's loss of 4.61% and the S&P 500's loss of 0.97% in that time. Investors will be eagerly watching for the performanc ...

In the latest trading session, Astrazeneca (AZN) closed at $75.05, marking a -1.12% move from the previous day. This change lagged the S&P 500's daily loss of 0.03%. Meanwhile, the Dow lost 0.61%, and the Nasdaq, a tech-heavy index, added 0.56%. The pharmaceutical's stock has dropped by 2.92% in the past month, exceeding the Medical sector's loss of 4.4% and lagging the S&P 500's gain of 1.39%. The investment community will be paying close attention to the earnings performance of Astrazeneca in its upcoming ...

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday. The company agreed with AstraZeneca Plc's AZN Alexion for an exclusive worldwide license to ALXN-1840 (bis-choline tetrathiomolybdate) for Wilson's disease. Monopar will be responsible for all future global development and commercialization activities. Also Read: Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today Under the terms of the license agreement, Monopar will pay Alexion an upfront cash payment and equity in Monopar. Future p ...

Core Insights - Eccogene has announced a $60 million payment from AstraZeneca due to the successful achievement of milestones in the development of ECC5004/AZD5004, marking a significant step in its clinical trials [1][2] - The drug ECC5004/AZD5004 is currently undergoing two global Phase 2b trials aimed at treating obesity and type 2 diabetes, targeting participants who are obese or overweight with related comorbidities [1][2] Company Overview - Eccogene is a clinical-stage biopharmaceutical company focused on developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions [4] - The company retains co-development and co-commercialization rights for ECC5004/AZD5004 in China, having previously licensed global rights to AstraZeneca for an upfront payment of $185 million and potential future milestones totaling up to $1.825 billion [2][4] Drug Development and Pipeline - ECC5004/AZD5004 is an oral small molecule GLP-1 receptor agonist that has advanced into Phase 2b clinical trials, which is seen as a validation of Eccogene's translational research platform [2][3] - Eccogene is also advancing a pipeline of next-generation oral therapeutics, including a clinical-stage THR-β agonist and SSAO inhibitor, which may enhance the efficacy of GLP-1 receptor agonists in treating obesity-related comorbidities [3][4] Market Context - The prevalence of obesity and its associated comorbidities affects over one billion people globally, highlighting the urgent need for effective treatments [2] - AstraZeneca emphasizes the importance of rapidly progressing AZD5004 as a novel solution for patients facing interrelated cardiometabolic diseases and the risks associated with type 2 diabetes and obesity [3]